Lung cancer

BI 1479-0008 (BEAMION LUNG 2)

Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled,;multi-centre trial evaluating orally administered;BI 1810631 compared with standard of care as first-line treatment;in patients with unresectable, locally advanced or metastatic nonsquamous;non-small cell lung cancer harbouring HER2 tyrosine;kinase domain mutations.
  • Open at Paris since : 28/06/2024
  • Target : Adult
  • Phase : Phase III

Trial description

The primary objective of the trial is to show superiority of;zongertinib (BI 1810631) over SoC (pembrolizumab plus platinumpemetrexed;chemotherapy) based on the hazard ratio of progressionfree;survival (PFS) in patients diagnosed with unresectable, locally;advanced or metastatic histologically documented non-squamous;NSCLC with HER2 TKD mutations who have not received any;systemic treatment in this setting.
Url of the trial

Main investigator

NICOLAS GIRARD

Professeur - Médecin

Contact